HUTCHMED (China) (HKSE:00013) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:00013 HUTCHMED (China) Ltd HKSE:00013
81 GF Score
Price HK$19.41
GF Value HK$20.19
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is HUTCHMED (China) Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

HKSE:00013
81GF Score
HUTCHMED (China) Ltd HKSE:00013
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is HUTCHMED (China) (HKSE:00013) Overvalued in 2026?

Based on GuruFocus' analysis, HUTCHMED (China) stock appears to be undervalued. The current stock price of HK$19.41 is trading 3.9% below its estimated GF Value™ of HK$20.19. GuruFocus considers HUTCHMED (China) to be Fairly Valued.

Key valuation signals for HKSE:00013:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: HK$20.19 vs. price of HK$19.41 (3.9% below fair value)
  • GF Score™: 81/100 with 8 warning signs

No single metric tells the full story. See the HKSE:00013 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HUTCHMED (China) Business Description

Address 2 Queen's Road Central, 48th Floor, Cheung Kong Center, Hong Kong, HKG
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
81GF Score

Get the complete analysis for HKSE:00013

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$19.41
Price
HK$20.19
GF Value